A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Key Points • Parsaclisib, a highly selective, potent PI3Kδ inhibitor, demonstrated durable responses and an overall manageable safety profile in R/R MZL.• Investigation is needed to determine patients who may benefit from PI3K pathway inhibition as an alternative to standard-care agents used for second-line and beyond.

[1]  D. Demarini,et al.  Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study , 2023, EClinicalMedicine.

[2]  P. Venugopal,et al.  Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study , 2023, EClinicalMedicine.

[3]  I. Lossos,et al.  A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma , 2022, British journal of haematology.

[4]  A. Zelenetz,et al.  Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. , 2022, The Lancet. Oncology.

[5]  R. Pazdur,et al.  The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. , 2022, The Lancet. Oncology.

[6]  I. Lossos,et al.  Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204) , 2021, Blood.

[7]  R. Marcus,et al.  The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma , 2021, Clinical Cancer Research.

[8]  J. Burke,et al.  Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Wei Jiang,et al.  Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) , 2020 .

[10]  T. Phillips,et al.  Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma? , 2020, Clinical lymphoma, myeloma & leukemia.

[11]  H. Koblish,et al.  Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[12]  A. Salar,et al.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Lenz,et al.  Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study , 2019, American journal of hematology.

[14]  H. Koblish,et al.  INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ). , 2019, ACS medicinal chemistry letters.

[15]  D. Demarini,et al.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. , 2019, Blood.

[16]  J. Gribben,et al.  AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Flowers,et al.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. , 2017, Blood.

[19]  C. Flowers,et al.  New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy , 2015, Expert review of anticancer therapy.

[20]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[22]  E. Jaffe,et al.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.